These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

55 related articles for article (PubMed ID: 19332712)

  • 1. CALGB 9633: an underpowered trial with a methodologically questionable conclusion.
    Katz A; Saad ED
    J Clin Oncol; 2009 May; 27(13):2300-1; author reply 2301-2. PubMed ID: 19332712
    [No Abstract]   [Full Text] [Related]  

  • 2. Lung cancer may be different for men and women, but researchers ponder what to do?
    Hede K
    J Natl Cancer Inst; 2007 Dec; 99(24):1830-2. PubMed ID: 18073369
    [No Abstract]   [Full Text] [Related]  

  • 3. NSCLC--platinum or not.
    Androulakis N; Georgoulias V
    Lung Cancer; 2005 Mar; 47(3):381-3. PubMed ID: 15713521
    [No Abstract]   [Full Text] [Related]  

  • 4. Adjuvant chemotherapy for non-small-cell lung cancer: a fading effect?
    Besse B; Le Chevalier T
    J Clin Oncol; 2008 Nov; 26(31):5014-7. PubMed ID: 18809602
    [No Abstract]   [Full Text] [Related]  

  • 5. [Clinical investigation of weekly Carboplatin and Paclitaxel with concurrent radiation therapy for locally advanced non-small cell lung cancer].
    Mito A; Yamasaki M; Matsuura K; Kajihara T; Nitta T; Awaya H; Arita K; Kashiwado K; Ohashi N
    Gan To Kagaku Ryoho; 2009 Oct; 36(10):1653-6. PubMed ID: 19838022
    [TBL] [Abstract][Full Text] [Related]  

  • 6. VEGF in patients with non-small cell lung cancer during combination chemotherapy of carboplatin and paclitaxel.
    Shingyoji M; Ando S; Nishimura H; Nakajima T; Ishikawa A; Itakura M; Iizasa T; Kimura H
    Anticancer Res; 2009 Jul; 29(7):2635-9. PubMed ID: 19596939
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Platinum-based second-line treatment in non-small-cell lung cancer: an old new kid on the block?
    de Lima Araújo LH; Ferreira CG
    J Clin Oncol; 2010 Jan; 28(2):e24-5; author reply e26. PubMed ID: 19933903
    [No Abstract]   [Full Text] [Related]  

  • 8. Phase II study of ASA404 (vadimezan, 5,6-dimethylxanthenone-4-acetic acid/DMXAA) 1800mg/m(2) combined with carboplatin and paclitaxel in previously untreated advanced non-small cell lung cancer.
    McKeage MJ; Reck M; Jameson MB; Rosenthal MA; Gibbs D; Mainwaring PN; Freitag L; Sullivan R; Von Pawel J
    Lung Cancer; 2009 Aug; 65(2):192-7. PubMed ID: 19409645
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dose-escalating and pharmacokinetic study of a weekly combination of paclitaxel and carboplatin for inoperable non-small cell lung cancer: JCOG 9910-DI.
    Naoki K; Kunikane H; Fujii T; Tsujimura S; Hida N; Okamoto H; Watanabe K
    Jpn J Clin Oncol; 2009 Sep; 39(9):569-75. PubMed ID: 19520687
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Reporting of subset analysis: where do we draw the line?
    Goel S
    J Clin Oncol; 2008 Apr; 26(12):2062-3; author reply 2064-5. PubMed ID: 18421065
    [No Abstract]   [Full Text] [Related]  

  • 11. Progress in small-cell lung cancer: the lowest common denominator.
    Gandara DR; Lara PN; Natale R; Belani C
    J Clin Oncol; 2008 Sep; 26(26):4236-8. PubMed ID: 18779609
    [No Abstract]   [Full Text] [Related]  

  • 12. Re: 'A threefold dose intensity treatment with ifosfamide, carboplatin, and etoposide for patients with small-cell lung cancer: a randomized trial'.
    Bregni M; Pedrazzoli P
    J Natl Cancer Inst; 2009 Jan; 101(1):67; author reply 67-8. PubMed ID: 19116385
    [No Abstract]   [Full Text] [Related]  

  • 13. The incidence of perioperative anastomotic complications after sleeve lobectomy is not increased after neoadjuvant chemoradiotherapy.
    Milman S; Kim AW; Warren WH; Liptay MJ; Miller C; Basu S; Faber LP
    Ann Thorac Surg; 2009 Sep; 88(3):945-50; discussion 950-1. PubMed ID: 19699925
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Do the time to chemotherapy response and the dose intensity have an impact on patient outcome in advanced non-small cell lung cancer?
    Radosavljevic D; Golubicic I; Gavrilovic D; Kezic I; Jelic S
    J BUON; 2009; 14(2):203-9. PubMed ID: 19650167
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Carboplatin-pemetrexed adjuvant chemotherapy in resected non-small cell lung cancer (NSCLC): a phase II study.
    Karapanagiotou EM; Boura PG; Papamichalis G; Konstantinou M; Sepsas E; Chamalakis G; Simsiris P; Gkiozos I; Syrigos KN
    Anticancer Res; 2009 Oct; 29(10):4297-301. PubMed ID: 19846990
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase II study of the combination of nedaplatin and weekly paclitaxel in patients with advanced non-small cell lung cancer.
    Hirose T; Sugiyama T; Kusumoto S; Shirai T; Nakashima M; Yamaoka T; Okuda K; Ogura K; Ohnishi T; Ohmori T; Adachi M
    Anticancer Res; 2009 May; 29(5):1733-8. PubMed ID: 19443395
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Advanced lung cancer: progress in individualized therapy].
    Bischoff A
    MMW Fortschr Med; 2009 May; 151(21):20. PubMed ID: 19537631
    [No Abstract]   [Full Text] [Related]  

  • 18. Re: Anti-angiogenic therapy using thalidomide combined with chemotherapy in small cell lung cancer: a randomized, double-blind, placebo-controlled trial.
    Musallam KM; Taher AT
    J Natl Cancer Inst; 2009 Dec; 101(23):1657; author reply 1657-8. PubMed ID: 19858426
    [No Abstract]   [Full Text] [Related]  

  • 19. Re-evaluating duration of therapy in advanced non-small-cell lung cancer: is it really duration or is it more about timing and exposure?
    Socinski MA
    J Clin Oncol; 2009 Jul; 27(20):3268-70. PubMed ID: 19470913
    [No Abstract]   [Full Text] [Related]  

  • 20. [Combination chemotherapy for treatment of metastasing non-small-cell lung carcinoma. Monotherapy of combinations of two or three agents--a survey of a Cochrane review].
    Mellemgaard A; Pappot H
    Ugeskr Laeger; 2009 Jun; 171(25):2084-7. PubMed ID: 19671386
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 3.